24 weeks open-label study with dupilumab and narrowband UVB phototherapy three times weekly for 12 weeks followed by 12 weeks of dupilumab monotherapy.
No linked publications found in PubMed
Inclusion Criteria: * Male or female adult ≥ 18 years of age; * Diagnosis of moderate to severe atopic dermatitis as defined at baseline by: * EASI score of 16 or greater, * IGA score of 3 or greater * BSA of 10% or greater, Exclusion Criteria: * Subjects with previous exposure to dupilumab. * Known or suspected hypersensitivity to dupilumab or any of its excipients. * History of photosensitivity.